Severe Exacerbations of Non-Cystic Fibrosis Bronchiectasis Requiring Hospitalisation: Microbiology and Inpatient Management in a Tertiary Care Centre
Background: Hospitalised exacerbations of non-cystic fibrosis bronchiectasis are clinically heterogeneous, yet inpatient microbiology and management remain incompletely characterised. Methods: We retrospectively analysed 53 consecutive hospitalisations in 47 adults (2023–2024), describing respiratory severity, microbiological findings, antimicrobial exposure, corticosteroid use and length of stay (LOS), without a comparator group. Results: Acute respiratory failure was documented in 12/53 episodes (22.6%), and Pseudomonas aeruginosa was isolated in 19/53 (35.8%). An exploratory four-domain classification (bacteria, nontuberculous mycobacteria, fungi and viruses), incorporating historical and acute findings, identified ≥2 domains in 24/53 episodes (45.3%); median LOS was 18.5 versus 15 days for ≥2 versus 0–1 domains. Intravenous antibacterials were recorded in 51/53 episodes (96.2%) and inhaled amikacin in 28/53 (52.8%). Median systemic antibacterial treatment duration, calculated from recorded concurrent antibiotic courses, was 11 days during hospitalisation and 11.5 days including documented pretreatment. Systemic corticosteroids were recorded in 28/53 episodes (52.8%), including 15/30 without documented COPD or asthma. Overall median LOS was 16 days (IQR 12–20), with one in-hospital death (1.9%). Conclusions: Hospitalised exacerbations involved heterogeneous microbiological findings and frequent acute inhaled antibiotic and systemic corticosteroid use. The overlap–LOS contrast is descriptive, not prognostic, and reconstructed durations cannot establish treatment appropriateness. Prospective studies should assess prescribing indications, microbiological context and clinical response.
Authors
- Alessandro Cascina (ORCID: https://orcid.org/0000-0002-5725-5309)
- Valentina Conio
- Angelo Guido Corsico (ORCID: https://orcid.org/0000-0002-8716-4694)
- Giulia Maria Stella (ORCID: https://orcid.org/0000-0003-0929-4394)
- Francesco Rocco Bertuccio (ORCID: https://orcid.org/0009-0009-7699-6610)
- Paolo Cosseta Reposi
- Lorenzo Arlando (ORCID: https://orcid.org/0009-0009-9805-5205)
- Lucrezia Pisanu
- Mitela Tafa
- Maria Arminio (ORCID: https://orcid.org/0009-0001-6875-3987)
- Elisabetta Gallo
Institutions
- University of Pavia (IT)
- Policlinico San Matteo Fondazione (IT)
Publication Details
- Journal
- Diseases
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3390/diseases14110427
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00